Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GKIND015A
- Development stage
- Preclinical
- Lead developer
- China Resources Pharmaceutical Commercial Group International Trading
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GKIND015A is a small molecule multi-target kinase inhibitor currently in preclinical development by China Resources Guokang Pharmaceutical. The drug is being investigated for the treatment of liver cancer, where it aims to inhibit multiple kinase signaling pathways that drive tumor growth and survival. As of the latest pipeline updates, GKIND015A is at the lead compound stage of development.
Beyond the preview
Go deeper on GKIND015A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GKIND015A.